The Pharmaceutical Benefits Advisory Committee will reconsider Novo Nordisk's WEGOVY (semaglutide) for weight loss at its November meeting, and other sectors might be watching, based on one analyst's assessment. …
New analysis reveals potential economy-wide impact of weight-loss therapies
October 3, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
FDA invites submissions to new rapid review priority program
July 25, 2025 - - Latest News -
Pharmac marks 12-month anniversary of funding boost
July 25, 2025 - - Latest News -
AccessCR announces finalists in Consumer Partnerships in Research Awards
July 24, 2025 - - Latest News -
Australian Life Sciences Venture Capital firm Brandon Capital announces Fund Six final close
July 24, 2025 - - Australian Biotech -
Australia on the list of countries to be targeted over pharmaceutical pricing
July 24, 2025 - - Latest News -
Latest trade agreements reveal US focus on resolving longstanding issues
July 24, 2025 - - Latest News -
Sanofi to acquire Vicebio, gaining rights to Queensland discovered technology
July 23, 2025 - - Australian Biotech